Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages


The myRisk Hereditary Cancer Test
helps you make the decisions that matter most

Knowing your patient’s hereditary cancer risk is critical when it comes to making treatment decisions. Blending both genetic test status and personal cancer family history, the Myriad myRisk® hereditary cancer panel represents the next generation of hereditary cancer risk testing. Myriad myRisk is here to help you determine the right treatment for your patients with a report including comprehensive results and a guideline-based Medical Management Tool.

Offer Myriad MyRisk Testing

Genes Icon


3 out of 4 patients pay $0

Genes Icon


Average turnaround time is 7-14 days

Genes Icon


We make genetic testing simple for your patients and your practice

Myriad is Your Trusted Advisor

  • 27+ years of experience in hereditary cancer testing
  • Analytically validated high-throughput sequencing
  • Industry leading variant classification program
  • Lifetime commitment to variant classification & result updates

Commitment to Providing Broad Patient Access

  • Myriad works directly with patients to provide up front clarity and resolve questions about cost (cost estimator coming soon)
  • Affordability options personalized to patients’ unique needs
  • 97% of private insurance have coverage for testing
  • Pre-test counseling services to educate patients on HC testing (post-test coming soon)
  • 90% of patients have or will qualify for a payment of $100 or less

myRisk is Identifying Risk for Your Patients

myRisk Hereditary Cancer Panel

Multi-gene panel determines hereditary cancer risk associated with 8 cancer sites:

  • Breast
  • Ovarian
  • Colorectal
  • Endometrial
  • Melanoma
  • Pancreatic
  • Gastric
  • Prostate
myRisk Management Tool (MMT)

The myRisk test report provides recommendations for managing patients with both positive AND negative genetic results. Every report includes the myRIsk Genetic Result and a personalized myRisk Medical Management Tool based on professional society guidelines.

Learn More


In the past, family history screening has been too complex and time consuming. myGeneHistory is a simple patient friendly questionnaire that patients take before arriving or in your office. Patients input personal and family history into myGeneHistory. Once completed, the patient and you will be informed if they meet guidelines for genetic testing. Results from myGeneHistory are automatically saved into your MyriadPro account where you’ll be able to order Myriad genetics tests quickly and easily.

Learn about the benefits of myGeneHistory and how to implement it into your practice.

Get Started with myGeneHistory

Variant Classification

Myriad is the unquestioned industry leader in variant classification and reclassification. myVision™ is the most advanced program in the industry overseeing the classification and reclassification of uncertain variants and is part of Myriad’s commitment to patients and their families.


Variants Classified in 2016


Variants Re-classified in 2016


Amended Reports Issued in 2016

Advancing the Science

Myriad is dedicated, above all else, to improving patient care through pioneering research and the development of innovative molecular diagnostic tests. Since 1991, Myriad has invested more than a billion dollars to enhance the world’s collective scientific understanding of disease through collaborative research, outreach and education and to translate that knowledge into molecular and companion diagnostic tools that save and improve the lives of the patients we serve.

Why Choose Myriad?

Genes Icon


Scientific publications consisting of clinically meaningful information have been published in peer reviewed journals over the past 5 years

Genes Icon

$341.7 Million

Invested in research over the past 5 years

Genes Icon


Academic institutions have collaborated with Myriad to help advance medical and scientific knowledge and healthcare overall. You can view a list of these institutions here.